- Home
- KALU vs CDNA Comparison
KALU vs CDNA Comparison
Compare KALU & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- CDNA
- Stock Information
- Founded
- KALU 1946
- CDNA 1998
- Country
- KALU United States
- CDNA United States
- Employees
- KALU N/A
- CDNA N/A
- Industry
- KALU Metal Fabrications
- CDNA Medical Specialities
- Sector
- KALU Industrials
- CDNA Health Care
- Exchange
- KALU Nasdaq
- CDNA Nasdaq
- Market Cap
- KALU 1.1B
- CDNA 1.1B
- IPO Year
- KALU 1991
- CDNA 2014
- Fundamental
- Price
- KALU $71.71
- CDNA $25.07
- Analyst Decision
- KALU Buy
- CDNA Buy
- Analyst Count
- KALU 3
- CDNA 8
- Target Price
- KALU $82.33
- CDNA $27.17
- AVG Volume (30 Days)
- KALU 105.9K
- CDNA 725.3K
- Earning Date
- KALU 02-19-2025
- CDNA 02-26-2025
- Dividend Yield
- KALU 4.31%
- CDNA N/A
- EPS Growth
- KALU 252.66
- CDNA N/A
- EPS
- KALU 2.90
- CDNA N/A
- Revenue
- KALU $2,980,300,000.00
- CDNA $312,775,000.00
- Revenue This Year
- KALU N/A
- CDNA $19.85
- Revenue Next Year
- KALU $6.84
- CDNA $11.34
- P/E Ratio
- KALU $24.59
- CDNA N/A
- Revenue Growth
- KALU N/A
- CDNA 5.26
- 52 Week Low
- KALU $59.52
- CDNA $7.42
- 52 Week High
- KALU $102.42
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- KALU 43.21
- CDNA 63.83
- Support Level
- KALU $68.02
- CDNA $22.00
- Resistance Level
- KALU $72.46
- CDNA $21.68
- Average True Range (ATR)
- KALU 2.10
- CDNA 1.20
- MACD
- KALU 0.28
- CDNA 0.44
- Stochastic Oscillator
- KALU 84.34
- CDNA 96.50
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.